Our latest press releases, media appearances and news commentary.
Our Chief Informatics Officer, Professor John Overington, supports Prime Minister Theresa May’s plans to use AI as a weapon for fighting cancer.
Medicines Discovery Catapult, the Centre for Drug Safety Sciences at the University of Liverpool and the NC3Rs combine forces.
CEO, Chris Molloy, responds to the findings and recommendations.
Mark Samuels, our Chief Business & Strategy Officer, was recently profiled in PharmaTimes.
CEO, Chris Molloy, has an article featured at Open Access Government.
Tissue Solutions and Medicines Discovery Catapult launch service to support UK companies and biobanks.
New drug discovery research to tackle the growing health epidemic of antimicrobial resistance will soon be underway.
UK pharma R&D productivity is at an all-time low, warns our CEO Chris Molloy.
Peter will be joining their board this year along with Emilio Diez Monedero and Severine Tamas-Lhoustau.
The Medicines Discovery Catapult and BioIndustry Association call on the R&D community to address five themes to help boost productivity.
See how we can help support you with your next drug discovery project.
Speak to us